share_log

Fudan-Zhangjiang Bio-Pharma Enrolls First Patient in US Phase 2 Trial for Birthmark Treatment

Fudan-Zhangjiang Bio-Pharma Enrolls First Patient in US Phase 2 Trial for Birthmark Treatment

復旦-張江生物製藥公司在美國進行的第二階段試驗中首位患者入組,用於治療胎記。
MT Newswires ·  09/24 04:09

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論